Latest News
Dyne Therapeutics, Inc.
- Dyne Therapeutics, Inc. Estimates – NASDAQ:DYN
- Form 4 Dyne Therapeutics Inc: Douglas Kerr (Head of R&D and CMO) For: 20 October
- Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?
- Dyne presents new exon skipping conjugates for DMD
- Dyne Therapeutics (DYN) Edges Lower to $16.11, Holding Above $15.30 Support - Jelly Roll Trade
- Dyne Therapeutics rated 'risky Buy' after 30% d...
- Jefferies reiterates Dyne Therapeutics stock rating on trial data
- Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1
- Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN)
- Stifel reiterates Dyne Therapeutics stock rating on trial data
- Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
- Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence
Headlines from the last 30 days, linking to the original publishers. See all market news →